Aarti Drugs Ltd

- The company anticipates a total capital expenditure of roughly INR200 crores for the full year, mainly funded through internal accruals and partly through term loans. - There is no explicit mention of new fundraising through equity in the transcript. - The company completed a buyback of 665,000 equity shares at INR900 per share in September 2024. - Overall, the company appears to rely mostly on internal accruals and some term loans for funding its ongoing capex and growth projects. - No specific plans for fresh debt or equity issuance were disclosed during the call.

- The greenfield Specialty Chemicals plant at Saykha is complete, with trials started; main plant trials to begin by mid-to-end November 2024. - Planned capex for the current year is roughly INR200 crores, funded mainly internally with some term loans. - Ongoing capex includes capacity expansion, backward integration, and new product launches; around INR90 crores spent in H1 FY25. - The Saykha greenfield project expected to come on stream by Q3 or Q4 FY25, moving roughly INR300 crores from CWIP to fixed assets. - Small brownfield expansions are in progress for cardio protectants and anti-diarrheal products, with anti-diarrheal facility starting soon. - Future capex plans exist but are still on paper pending product finalization; FY27 turnover expected between INR3,500-4,000 crores. - Capacity expansion plans include scaling metformin up from current 1,350-1,400 tons/month to 1,700-1,800 tons/month post land acquisition. - Focus on improving operational efficiencies and power cost via renewable energy investments.

- FY '25 sales expected to be flattish compared to FY '24 due to lackluster demand and negative rate variance despite volume growth. - FY '26 anticipated as a turnaround year driven by ramp-up and streamlined operations of the Salicylic Acid plant. - Formulation business has strong order book (~$12 million) and export potential; growth expected in coming 2-3 quarters. - Specialty Chemicals plant at Saykha to start production trials by November; long-term EBITDA potential of ~INR40 crores. - Revised sales guidance now INR3,500 crores to INR4,000 crores for next 2-3 years, down from earlier INR4,200 crores-4,500 crores guidance, largely due to current API pricing. - Metformin capacity planned to scale from current ~1,350-1,400 tons/month to 1,700-1,800 tons/month short term, and up to 3,000 tons/month longer term. - API segment volume utilization at 78%, with scope for growth via capacity expansions and new products. - Overall long-term EBITDA margin target around 14.5%-15.5%.

- Aarti Drugs Limited targets long-term EBITDA margins of 14.5% to 15.5%, aiming to restore historical profitability levels. - Current pricing levels have led to revised revenue potential of INR 3,500 to 4,000 crores in the medium term (previously INR 4,200 to 4,500 crores). - FY '25 is expected to be flattish in revenue due to subdued demand and pricing but FY '26 is seen as a turnaround year driven by ramp-up of Salicylic Acid capacity and improved operating leverage. - Specialty Chemicals plant at Saykha to contribute approximately INR 40 crores to EBITDA in the longer term. - Increased product registrations and export orders in formulation business with a strong order book (~$12 million) indicate growth prospects. - Capex largely complete by FY '25 end; further expansions planned mainly through brownfield projects to support growth beyond INR 3,500 crores turnover by FY '27. - Ramp-up of metformin and other high-margin products is expected to improve earnings visibility in coming quarters.

- The formulation business has a strong order book of over $12 million as of the September quarter. - Despite nominal sales of $2 million to $2.5 million in the September quarter, the robust order book indicates a significant export potential. - The Specialty Chemicals plant at Saykha is starting trials in November, expected to contribute long-term EBITDA of around INR 40 crores. - Upcoming production from the Specialty Chemicals plant will mostly serve captive consumption with some volume for external sales. - Export markets have started showing demand uptick, indicating potential growth in order inflows. - Overall, Aarti Drugs Limited anticipates picking up formulation business growth over the next 2 to 3 quarters supported by a strong order pipeline.